TargImmune Therapeutics AG is a private Swiss-based biotechnology company developing a novel targeted cancer treatment modality. TargImmune has a unique dsRNA non-viral vector delivery platform which, by mimicking a virus, harnesses the body's powerful antiviral defenses to address cancer tumors including distant metastases. The targeted nanoparticles drive a combination of apoptosis (cell death) and modulation of the innate and adaptive immune cells to target both primary and metastatic heterogeneous tumour cells. TargImmune’s therapeutics are the first in a new class known as Targeted Apoptotic Immune Modulators (TAIMs). TargImmune’s unique viral mimicry approach is fundamentally different to any of the other classes of anticancer agents in the clinic and has the potential to transform outcomes for cancer patients.
View Top Employees from TargImmune Therapeutics AGWebsite | https://targimmune.com |
Revenue | $5 million |
Employees | 20 (16 on RocketReach) |
Founded | 2016 |
Address | Hochbergerstrasse 60c, Basel, Basel City 4057, CH |
Phone | +41 61 633 29 89 |
Industry | Pharmaceutical Manufacturing, Medical Testing & Clinical Laboratories, Biotechnology, Healthcare, Science and Engineering, Pharmaceutical, Health Care |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5413 Companies, NAICS Code 54138 Companies |
Looking for a particular TargImmune Therapeutics AG employee's phone or email?
The TargImmune Therapeutics AG annual revenue was $5 million in 2024.
Peter Braun is the CEO of TargImmune Therapeutics AG.
16 people are employed at TargImmune Therapeutics AG.
TargImmune Therapeutics AG is based in Basel, Basel City.
The NAICS codes for TargImmune Therapeutics AG are [54, 541, 5413, 54138].
The SIC codes for TargImmune Therapeutics AG are [873, 87].